Selank, originally formulated in Russia, is a brief peptide renowned for its nootropic and anxiolytic attributes. It serves as a synthetic counterpart to the naturally existing Tuftsin, an immunomodulatory peptide influencing IL-6, T helper cells, monoamine neurotransmitters, and brain-derived neurotropic factor (BDNF). Notably, Selank and Tuftsin share similar structures, with Selank incorporating four extra amino acids in its composition, enhancing its metabolic stability and prolonging its half-life. Clinical trials have explored the potential of Selank as a treatment option for generalized anxiety disorder.

This section summarizes the dosing and cycling guidance as listed for Selank, plus the noted cautions/contraindications and common vial-format options. (Educational context only.)

Dosing & Cycling (As Listed):The source provides a per-dose range and a suggested cycling pattern (rather than a fixed week-by-week escalation schedule).

Notes on modified forms: The source notes limited research on dosing/cycling schemes for Selank modifications (N-Acetyl and Amidate). Currently, dosing and cycling schemes similar to the original compound are described in the peptide field. It also notes it’s often recommended to start with a more conservative dosing/cycling scheme when researching a more potent compound.

Caution & Contraindications:
Caution:
• May cause headache, fatigue, and/or anxiety
• Use caution in individuals taking other antidepressants or antipsychotics
Contraindications:
• Generally well tolerated based on current research

Reconstitution Options (Vial Format):
• 5 mg
• 10 mg

Reconstitution (General Handling):
• Use sterile technique and sanitize the vial stopper before access.
• Reconstitute with bacteriostatic water; choose a volume that matches your desired concentration.
• Add diluent slowly along the vial wall to minimize foaming.
• Gently swirl/roll until fully dissolved (avoid vigorous shaking).
• Store refrigerated at 2–8 °C and protect from light as applicable.

Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro

Molecular Formula: C₃₃H₅₇N₁₁O₉

Molecular Weight: 751.89 g/mol

Synonyms: Tuftsin Analog

Selank’s impact on anxiety, as related to genes associated with the GABA neurotransmitter, has been a subject of interest. Dr. Anastasiya Volkova, from the Institute of Molecular Genetics in Russia, has conducted studies revealing that TP7 exhibits robust antianxiety and neuroprotective properties in anxiety treatment. Its clinical effects closely resemble those of conventional antianxiety medications like benzodiazepines, which act as allosteric modulators of GABAA receptors, intensifying the inhibitory effects of GABA. Selank’s benefits encompass anxiety reduction, mood enhancement, stress reduction, and positive influences on memory and learning. Interestingly, similar to benzodiazepines, TP7, when administered in low doses, can induce a calming effect. Importantly, unlike benzodiazepines, TP7 does not seem to promote dependency or trigger withdrawal symptoms or memory lapses.

Research conducted on rats indicates that Selank has a notable impact on genes connected to GABA signaling. Out of the 84 genes associated with GABA signaling in some manner, seven undergo substantial modulation when exposed to Selank, while 45 exhibit altered expression levels in response to the peptide. In total, TP7 affects 52 genes related to GABA signaling to varying degrees. These findings suggest that Selank has the capacity to directly influence gene expression within nerve cells, most likely by altering the affinity of GABA receptors for GABA. This change in receptor affinity provides insight into why Selank demonstrates synergy with benzodiazepines and other GABA receptor agonists.

Selank’s Impact on Anxiety and Its Combination with Benzodiazepines Research conducted on rats suggests that Selank and benzodiazepines have similar effects on anxiety, especially in cases of generalized anxiety disorder (GAD). Selank may offer a slight advantage over benzodiazepines in reducing elevated anxiety levels. However, a combination of both treatments appears to be the most effective approach for treating unpredictable chronic mild stress.

Selank’s Influence on GABA Receptors and Enkephalin Degradation Selank’s effects on GABA receptors may be partially modulated by its impact on enkephalin degradation. Individuals with anxiety and phobic disorders often exhibit increased enkephalinase activity during generalized anxiety, leading to shorter half-lives of enkephalins. Selank, by inhibiting enkephalinase, may help reset this enzymatic pathway, protecting the body’s natural anxiolytic peptides. Research in anxiety-prone mice suggests that Selank’s effects are, in part, due to its ability to prevent enkephalin degradation.

It’s worth noting that Selank is associated with minimal side effects and excellent bioavailability in mice, though dosages in mice do not directly translate to humans. Selank is available for research purposes only and should not be consumed by humans without appropriate licensing.